A new injectable biomaterial developed by researchers at the University of California San Diego has shown promise for treating tissue damage caused by heart attacks and potentially other inflammation-driven conditions. In animal studies, the material, designed to travel through the bloodstream, demonstrated improvements in heart tissue recovery after cardiac events. This marks a significant shift from existing treatments, which primarily focus on restoring blood flow and managing complications rather than directly repairing damaged tissue.
The research team, led by bioengineering professor Karen Christman, published their findings in Nature Biomedical Engineering in 2022. Christman noted that the biomaterial could facilitate treatment from within the body, presenting a novel approach to regenerative engineering. Current therapies for heart attacks lack options for direct repair, highlighting the potential impact of this new method.
The biomaterial, derived from the extracellular matrix of cardiac tissue, can be infused into blood vessels during procedures like angioplasty or even delivered via IV. The study revealed that the material could localize to injured areas by binding to damaged blood vessels, potentially reducing inflammation and enhancing tissue healing. In rodent and porcine models, the treatment linked to improved heart function and gene expression associated with repair.
Looking beyond heart conditions, early experiments suggest that this biomaterial could also be effective for traumatic brain injuries and pulmonary arterial hypertension. As the research continues, Christman and her team plan to seek FDA approval for human trials to evaluate safety and efficacy. If successful, this innovative approach could transform treatment strategies for various difficult-to-access injuries and conditions.